WHO BENEFITED / WHAT WENT WRONG
What does PT-141 offer, and who faces risks?
Bremelanotide is a prescription medicine for distress over lost sexual desire. You can read who benefited from the shot, what brain tests found, and which problems came with treatment.
What’s the first thing to know?
Small chemicals joined into a short chain make PT-141 a peptide; those same chemicals also make proteins, the materials used to build your tissues and help the body do its work [1][7]. The drug’s ring shape and its brain action explain different things.
Under the name bremelanotide, PT-141 has approval for treating women’s distress over lost desire. Treatment covers women whose monthly periods haven’t ended with menopause and whose loss of desire causes distress [3][7].
Men’s treatment lacks approval, as does treatment after menopause or to improve sexual performance. PT-141 doesn’t boost testosterone, a hormone made in the body that helps govern desire [9].
The change in wanting sex begins with the drug’s effect within the brain. Feeling more desire doesn’t mean you have more testosterone.
The most frequent trial complaint was nausea, feeling sick to your stomach [4]. Drugs offered as “research chemicals” aren’t the approved prescription shot.
Those products are offered for experiments, without the checks required for medicines. You can’t assume their contents or strength match the medicine tested.
The PT-141 effects page covers both benefits and unpleasant effects. Read PT-141 mechanism of action to understand the brain findings.
What makes PT-141 harder for the body to break down?
PT-141 copies the action of a chemical made in your body [1][12]. Earlier tanning work on melanotan-II led to development of the medicine by Palatin Technologies [12].
The drug’s seven small chemical parts form a closed ring. The body breaks a straight chain apart more easily than this ring.
That resistance gives a shot time to act before breaking down [7]. The shape helps the drug last; the response in brain cells explains the effect on desire.
Cells are the tiny living parts that make up your body. PT-141 attaches to certain parts on the outside of cells, starting a response inside [1].
The responding cells help govern both emotion and the wish for sex. Scientists think a chemical called dopamine helps carry the response; the brain uses dopamine when controlling desire [5][11].
You can follow that response in how brain cells react. The ring’s lasting shape and the cells’ response explain different steps.
How did animals behave after the PT-141 peptide?
The PT-141 peptide comes from work on the tanning drug melanotan-II [1]. A chemical change separates this drug from the earlier tanning drug.
Natural body chemicals can start responses at five related parts on cells. Two of the parts found within the brain are the main points where PT-141 acts [1].
After receiving the drug, rats and animals related to monkeys developed erections. The erection response strengthened with larger amounts, while brain cell activity also increased in testing [1].
Female rats made more efforts to get males to mate. The drug didn’t increase back arching when mounted or movement overall [2].
No earlier drug had been reported to increase that mate-seeking behavior. You can’t count on an animal response happening in a person.
What changed for women during the brain tests?
Researchers scanned 31 women whose low sexual interest caused distress before their periods ended. Increased interest in sex lasted up to 24 hours after treatment [5].
The women viewed pictures meant to stir sexual interest during scans. Parts handling emotion and bodily feelings appeared to work together more closely.
Compared with earlier scans, activity in those parts changed together more strongly after treatment. The women’s answers separately described how desire felt.
Scans also detected changed activity in parts helping organize movement. Researchers measured brain activity, rather than testing the women’s movements.
Erection pills relax muscles in vessel walls, easing blood flow toward the penis. PT-141 leaves those muscles unaffected [10].
PT-141 stimulates cells governing the wish for sex [1][10]. You may have erection trouble even with strong sexual interest.
Read PT-141 mechanism of action for more on the tests. The erection-pill comparison explains the difference in action.
Which women can receive the medicine under its approval?
Bremelanotide received United States approval on June 21, 2019, for shots under the skin [7]. The approved treatment concerns women upset by losing desire before their monthly periods end.
Those women had normal desire before the loss began. Their loss of interest must extend across different partners, settings, and kinds of sex, rather than happen in just one circumstance.
In men, smaller Phase 2 trials tested erection problems without leading to approval [13]. Approval also excludes use after menopause, sexual performance, appetite, and weight-related illness.
A review judged the women’s improvement real, but small [14]. During longer treatment, about 40% felt sick, and some women stopped treatment [4].
The warnings rule out treatment when heart disease or blood vessel disease is known. A temporary blood pressure increase makes treatment unsuitable when existing high pressure is uncontrolled [7].
PT-141 products offered for experiments lack required testing to establish what’s inside, how pure it is, and its drug strength [9]. You can read PT-141 effects before weighing claims about benefits.
Where do people describe their own experience?
People describe desire, pleasure, and problems in the PT-141 reports. Their experiences can help you name a concern, but can’t prove its cause.